Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly
News Jul 23, 2009
Galapagos NV has announced that it has reached a milestone in its osteoporosis collaboration with Eli Lilly and Company, triggering a payment of €2.5 million from Lilly.
In December 2007, Lilly and Galapagos initiated an alliance to develop new medicines for the treatment of osteoporosis. The agreement provides Lilly access to 12 of Galapagos' novel target based programs in osteoporosis, with Galapagos responsible for the development of drug candidates through to Phase IIa clinical Proof of Concept.
The milestone announced is the result of one of these programs reaching the next phase of medicinal chemistry optimization. To date, Galapagos has received a total of €3.9 million in milestone payments from Lilly under the alliance.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE